The director of Nigeria’s National Agency for Food and Drug Administration and Control (Nafdac), Mojisola Adeyeye, has disclosed that clinical trails for virus treatment using chloroquine will continue despite a recent move by the WHO to suspend a similar trial over safety concerns. She told a local broadcaster that even though Nafdac did not dispute WHO ’s conclusions, the decision to continue with the trial was in order to generate their own data. “I do not know the data that they’re looking at, whether it’s from the Caucasian population or from the African population. If the data they’re looking at and the reason for suspending the trials is from Caucasian population, then it may be justified. “But I don’t think we have data from the African population yet, because our genetic make up is different,” she added. Lagos State had announced last week that trials were to start with the anti-malarial drug. READ MORE